The study of low abundant proteins contributes to increasing our knowledge about (patho)physiological processes and may lead to the identification and clinical application of disease markers. However, studying these proteins is challenging as high-abundant proteins complicate their analysis. Antibodies are often used to enrich proteins from biological matrices prior to their analysis, though antibodyfree approaches have been described for some proteins as well. Here we report an antibody-free workflow on the basis of strong cation exchange (SCX) enrichment and liquid chromatography-mass spectrometry (LC-MS) for quantification of the soluble Receptor of Advanced Glycation End-products (sRAGE), a promising biomarker in chronic obstructive pulmonary disease (COPD). sRAGE was quantified in serum at clinically relevant low to sub ng/mL levels. The method was validated according to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines and was compared to an antibody-based LC-MS sRAGE method. The SCXbased method builds upon the bipolar charge distribution of sRAGE, which has a highly basic N-terminal part and an acidic C-terminal part resulting in an overall neutral isoelectric point (pI). The highly basic N-terminal part (pI calculated = 10.3) allowed for sRAGE to be enriched by SCX at pH 10, a pH at which most serum proteins do not bind. This study shows that ion exchange-based enrichment is a viable approach for the LC-MS analysis of several low abundant proteins following a thorough analysis of their physical-chemical properties. Chapter V 89 SRAGE BY LC-MS AFTER ENRICHMENT BY SCX-SPE AT THE PROTEIN LEVEL | 5.1.
INTRODUCTION
The quantification of proteins in blood-based samples is one of the hallmarks of modern laboratory medicine and allows for the diagnosis and staging of disease as well as for monitoring disease progression and treatment efficacy. Blood is, however, a highly complex matrix with only a few proteins (e.g. albumin, immunoglobulins) accounting for most of the total protein content. 1 These high abundant proteins complicate the analysis of many other proteins and often need to be depleted to enable the detection of clinically relevant proteins of lower abundance. 2, 3 Antibody-based enrichment procedures are commonly used to enrich low abundant proteins prior to their quantification, yet it has been shown in recent years that antibodyfree workflows can quantify proteins in the ng/mL range as well. 4 Antibody-free workflows are based on specific properties of a target protein that allow it to be separated from most other proteins in a biological sample. For example, some small, hydrophobic proteins can be enriched following protein precipitation procedures in which these smaller proteins remain in solution while larger proteins denature and precipitate. 5 In addition, proteins exhibiting regions rich in histidine, cysteine, and/or tryptophan residues, which form complexes with transition metal ions (e.g. Zn 2+ , Cu 2+ , Ni 2+ , Co 2+ ), can be enriched by immobilized metal affinity chromatography (IMAC). 6 Solid-phase extraction (SPE) furthermore offers a range of options for efficient enrichment of protein subclasses with specific physical-chemical properties. For example, proteins with an elevated net negative or positive charge can be enriched by strong anion exchange (SAX) or strong cation exchange (SCX)-based procedures, respectively. 4 The soluble Receptor of Advanced Glycation End-products (sRAGE) is an example of a clinically relevant protein of low abundance, which can currently only be quantified using affinity ligands (e.g. antibodies). This protein is a circulating form of membrane-bound RAGE, an important receptor of the innate immune system that is involved in triggering and sustaining inflammation, in particular in the lungs. 7 sRAGE is formed after proteolytic cleavage of RAGE by metalloproteases (e.g. ADAM10, MMP9) or by alternative splicing of the AGER gene leading to the so-called endogenous secretory RAGE (esRAGE) splice variant. sRAGE is proposed to act as a decoy receptor for various pro-inflammatory RAGE ligands thereby attenuating inflammation. [8] [9] [10] [11] Several large-scale clinical studies advanced sRAGE as promising biomarker for chronic obstructive pulmonary disease (COPD), and sRAGE is currently being considered for biomarker qualification by the U.S. Food and Drug Administration (FDA). 12, 13 sRAGE is a member of the immunoglobulin superfamily and consists of three immunoglobulin-like domains, the N-terminal 'V domain', the 'C1 domain', and the C-terminal 'C2 domain', which together result in a fairly neutral isoelectric point (pI). 7, 8 However, the V domain of sRAGE displays a net positive charge at neutral pH due to 16 positively charged amino acids versus 7 negatively charged residues, whereas its C2 domain displays a net negative charge at neutral pH by carrying 10 negatively charged amino acids versus 3 positively charged residues (see Figure S-1) . The bipolar charge distribution of sRAGE thereby provides opportunities for ion exchange-based protein enrichment, which is not obvious when solely considering the average pI of this protein.
In this study, we developed an ion-exchange-based enrichment approach for the quantification of sRAGE in human serum by liquid chromatography-mass spectrometry (LC-MS) at clinically relevant low to sub ng/mL levels. In addition, we identified other low abundant proteins for which ion-exchange-based protein enrichment may represent an alternative to the commonly-used affinity-based strategies for quantification by LC-MS. 
EXPERIMENTAL SECTION

Chemicals and Materials
Serum Samples
Pooled human serum from Seralab (West Sussex, U.K.) was used directly as QC-low sample or was fortified with rh-sRAGE at two levels to obtain the QC-medium and QC-high samples.
Recovery and spike recovery experiments as well as shotgun proteomics experiments were carried out using six different sources of human serum from healthy subjects (all from Seralab).
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Calibrants and Internal Standard
rh-sRAGE was dissolved in Milli-Q water to obtain a 200 µg/mL solution (based on the quantity as declared by the supplier) which was diluted to 100 µg/mL with 10 mM phosphate buffered saline, pH 7.4. The resulting solution was sequentially diluted to 100 ng/mL with rat serum, and calibration samples were prepared at 0.2, 0.5, 1.0, 2.0, 5.0, 8.0 and 10.0 ng/mL in rat serum. The internal standard (IS) stock solution was prepared by mixing equimolar amounts of the two SIL-peptides (supplied as 5 pmol/µL solutions in 5% ACN) and subsequently diluting these peptides to 5 fmol/µL with 1% dimethyl sulfoxide (DMSO) in water.
SCX-Based sRAGE Enrichment
The supplied suspension of the SCX resin was homogenized by agitation and 100 µL of this suspension was transferred to a microcentrifuge tube. The resin was washed with 800 µL ethanol and then with 800 µL 20 mM ammonium acetate, pH 10 (SCX buffer) by gentle vortex-mixing after which the resin was pelleted by centrifugation (3,000 × g; 2 min), and the washing solution was discarded. Next, the resin was resuspended in 750 µL SCX buffer and 50 µL of serum (or calibrant) was added. After 15 minutes of incubation on a rotating wheel, the sample was briefly centrifuged to spin down droplets from the lid, and the resin was loaded into an empty SPE reservoir which was placed in a Varian Cerex TM SPE processor (positive pressure was applied to let solvents pass through the SPE reservoirs in a dropwise manner) and which had been rinsed with 1 mL water. The resin was subsequently washed with 
Targeted analysis by LC-MRM/MS
Method validation and comparison
The method was validated according to EMA and FDA guidelines by addressing the following criteria: selectivity (e.g. spike recovery), accuracy & precision, recovery, calibration curve, and stability (e.g. 6 days benchtop, 5× freeze-thaw, and 6 days autosampler (10 °C)). 14, 15 Samples were fortified with 5 ng/mL sRAGE either before or after SCX-SPE to obtain the pre-SCX-SPE spiked and post-SCX-SPE spiked samples for recovery assessment, respectively. For the spike-recovery experiments, samples were processed either directly or were fortified with 5 ng/mL sRAGE (before SCX-SPE) to obtain the non-spiked and spiked samples, respectively.
Furthermore, the method was compared with a previously developed immunoaffinity-LC-MS method for sRAGE quantification. 16 For this purpose, 40 serum samples were analyzed from a cross-sectional study (NCT00807469) within the University Medical Center Groningen (UMCG). 17 Ethical approval for this study had been granted by the UMCG's review board (METc 2008/136), and the study adheres to the Declaration of Helsinki. Blood samples were collected as described previously. 16 
Shotgun proteomics
Proteins enriched by SCX at pH 10 (see 'SCX-Based sRAGE Enrichment' paragraph above)
or SAX at pH 4 (SPE was performed following the same steps that are described in the 'SCX- 
RESULTS AND DISCUSSION
SCX-based protein enrichment
The bipolar charge distribution of sRAGE, which has an average pI of 7.8 (calculated using Expasy's ProtParam tool 19 for the extracellular domain of RAGE, Ala23-Ala342), formed the basis for protein enrichment based on ion-exchange solid-phase extraction. On the one hand, the C-terminal C2 domain of sRAGE with a pI of 4.6 (Pro227-Ser317) allowed for binding to the SAX material down to pH 6 (see Figure 1A) , while the N-terminal V domain with a pI of 10.3 (Ala23-Arg116) bound to the SCX material up to pH 10 (see Figure 1B ). The latter strategy was selected for quantitative method development given that most human proteins are acidic in nature. 20
Figure 1. Enrichment of endogenous sRAGE from serum by (A) strong anion exchange (SAX) and (B) strong cation exchange (SCX) solid-phase extraction (SPE) at different pH values. In these experiments, TSKgel
SuperQ-5PW SAX and TSKgel SP-5PW SCX resins were used and SPE conditioning, loading, and washing steps were performed as described in the 'Shotgun proteomics' paragraph of the experimental section. Next, sRAGE was eluted with 1M NaCl and 0.02% Tween-20 in 10 mM phosphate buffer, pH 7.2, which allowed the eluates to be directly processed with a previously developed sRAGE immunoaffinity enrichment procedure 16 in order to reduce sample complexity (mostly relevant for the pH 6-8 samples) which was required for mass spectrometric detection of endogenous sRAGE.
The SCX-based protein enrichment method was developed using highly cross-linked polymethacrylate beads functionalized with sulfopropyl groups. Resin was transferred into an empty SPE cartridge after incubation with serum under alkaline conditions (pH 10). Loading and washing were performed using a 20 mM ammonium acetate buffer, pH 10 (see Figure  S -2), sRAGE was eluted from the SCX material with 1% aqueous ammonia (pH appr. 11.5), and eluates were directly neutralized by collecting them in tubes containing 15% aqueous acetic acid (see Figure S -3). The eluate was subsequently dried to reduce the sample volume and to remove most of the ammonium acetate. Including a TCA precipitation step after SCX enrichment instead of drying the eluates was also tested and resulted in a faster protocol and cleaner samples. However, the corresponding protein pellets were fragile and detached easily from the walls of the tubes leading to outliers that were incompatible with a validated quantitative bioanalytical method. The TCA precipitation procedure was, however, used for the shotgun proteomic analyses (see protocol outlined in the 'Shotgun proteomics' paragraph of the Experimental Section and corresponding data in the 'Ion exchange-based protein enrichment for targeted protein bioanalysis by LC-MS' paragraph below). The recovery of a previously developed antibody-based enrichment procedure was 83% with a CV of 4% thereby being somewhat higher but equally reproducible. 16 For preparing the calibration curve, we found that a surrogate matrix of sufficient complexity (e.g. serum from other organisms) was required and that a simple, artificial matrix consisting of bovine serum albumin (BSA) in PBS gave very low sRAGE recovery. We reasoned that BSA will be depleted following SCX at pH 10, as this protein has a calculated pI of 5.6, and that the sample after SCX-SPE will have a very low remaining protein concentration thereby likely inducing adsorption of sRAGE after the enrichment procedure. Complex matrices, in turn, are expected to lead to co-enrichment of other proteins, which serve as carrier proteins preventing sRAGE adsorption. Rat serum was found to be a suitable surrogate matrix, as demonstrated by an average spike-recovery bias of 10% (see Table S -3), which is well within acceptable limits (± 15%). Accurate quantification of sRAGE at clinically relevant levels between 0.2 and 10 ng/mL was demonstrated for a 1/x weighted linear calibration model using 7 non-zero standards.
Quantitative assay development
Method validation.
Reaching the desired sensitivity was, however, challenging and considerable chemical background was observed in the chromatograms of the calibrants (see Figure S -4A), though acceptable biases and CVs within 10% were found for all calibrants (see Table S -4) . In comparison with an immunoaffinity-LC-MS method for sRAGE quantification 16 , chemical background was somewhat higher for samples that were prepared using the SCX-SPE method, as can be deduced from the selected ion chromatograms of six serum samples prepared with both methods (see Figure S -5A and S-5B). TCA precipitation after SCX enrichment reduced the chemical background (see Figure S -5C) illustrating the added benefit of incorporating such a step in the protocol, provided that this procedure can be performed in a reproducible manner without producing outliers.
Accuracy of the method was high with biases ranging from -7% to 7% for the three QCsamples, and precision was acceptable with CVs below or equal to 15% (see Tables S-5 to S-7).
Stability assessments indicated that storing samples for 6 days on the benchtop or subjecting them to 5 freeze-thaw cycles did not affect sRAGE levels (see Tables S-8 and S-9). Stability of the final peptide digests was furthermore assessed for up to 6 days of storage in the autosampler at 10 °C and corresponding biases and CVs were well within the acceptance limits (see Table   S -10). 
Method comparison
Agreement between the SCX-based LC-MS sRAGE method and a previously developed antibody-based LC-MS sRAGE method 16 was assessed on the basis of 40 clinical samples using linear regression and Bland-Altman plots (see Figure 2 ). Comparison between the two methods revealed moderate correlation (R 2 = 0.48) and an increasingly positive bias for the SCX-based method with increasing sRAGE concentrations relative to the antibody-based method. Different sRAGE levels have been reported before when comparing the antibodybased LC-MS method with a commercial ELISA (i.e. the Human RAGE Quantikine ELISA kit from R&D Systems), which represents the most frequently used sRAGE assay in clinical biomarker studies. 16 The ELISA was found to report 84% lower sRAGE levels compared to the antibody-based LC-MS method, while correlation between these assays was rather good with an R 2 of 0.79.
These differences indicate that the measured sRAGE concentration strongly depends on methodology even though all three methods represent validated assays. It is, for example, conceivable that the methods capture a different subset of sRAGE proteoforms or sRAGEcontaining complexes. sRAGE molecules are known to bind to each other as well as to several other proteins 7 , and the binding sites of antibodies may thereby become inaccessible. In addition, some proteoforms lack certain regions or feature specific posttranslational modifications which might interfere with an enrichment strategy. With respect to the ELISA and the antibody-based LC-MS method, a lack of binding capacity of the antibodies may furthermore be a reason for the lower levels reported by these assays. In fact, an insufficient binding capacity would affect higher protein levels disproportionally, in agreement with the increasingly positive bias for the SCX-based method shown in Figure 2 . However, it should be noted that the antibody-based LC-MS method was validated over a much wider concentration range than strictly needed for the 40 samples included in the method comparison. The increasingly positive bias of the SCX-based method relative to the immunoaffinity-based method might also be due to a lower affinity of sRAGE for the SCX material, which would affect lower concentrations to a greater extend. The linear response of rh-sRAGE spiked in rat serum for the calibration samples did, however, not indicate such an effect. A further caveat is that data based on rh-sRAGE may not be representative for endogenous sRAGE pointing to a general problem in biomarker research, namely the lack of well-characterized authentic protein standards.
Figure 2. Comparison between the SCX-based LC-MS method (SCX) and a previously developed antibodybased LC-MS method (Antibody) 16 using (A) linear regression and (B)
Bland-Altman plots.
Ion exchange-based protein enrichment for targeted protein bioanalysis by LC-MS
Unlike affinity ligands which enrich their targets from a biological matrix based on welldefined binding sites, ion exchange-based enrichment procedures yield a series of proteins with common physical-chemical properties with respect to number of charges and charge distribution under a given set of experimental conditions. Several other proteins are therefore expected to be co-enriched by the SCX-based method, and we aimed to identify more proteins by shotgun proteomics in the SCX eluate at pH 10. We extended these experiments to the enrichment of serum proteins on an SAX resin at pH 4 to investigate whether the principle holds for both types of ion exchangers. As expected, SCX-based enrichment led to considerably less complex samples compared to SAX, as reflected by 3 times higher total ion current and base peak chromatograms and twice as many identified proteins in the SAX-enriched samples. Table S-11 gives an overview of proteins that were identified in the SCX-or SAX-enriched fractions of six different serum samples after removing the top 20 high abundant blood proteins 3 and common contaminants such as keratins. Many of the proteins comprised medium to high abundant blood proteins such as apolipoproteins, coagulation-related proteins or proteins of the complement system, yet some clinically relevant, lower abundant proteins were identified as well. When viewing these results, it must be kept in mind that MRM-based targeted protein analyses are more sensitive than shotgun analyses due to the stochastic nature of DDA. It is thus not surprising that sRAGE, the protein biomarker that we quantified in the SCX fraction, was not identified in any of the shotgun analyses. Figure 3 shows the calculated pI values of the proteins included in Table S-11 plotted against their concentrations in the circulation, as retrieved from the Plasma Proteome Database. 24 Based on the scatter observed in both plots we concluded that the (calculated) average pI is rather uninformative when aiming to predict the ion exchange behavior of proteins. The SCX fraction, for example, contained the low µg/mL insulin-like growth factor binding protein 
CONCLUSIONS
Protein enrichment is a prerequisite for many biological, biomedical, and clinical studies. The availability of good quality antibodies and other affinity ligands have opened up and expanded opportunities to study proteins for researchers working in biological and medical sciences.
Methods that do not rely on affinity ligands are, however, also suitable to enrich proteins from complex biological matrices with protocols that are as simple and straightforward as those of affinity-based methods. These methods take the specific physical-chemical characteristics of a protein of interest into account, such as the presence of transition metal-chelating sites, which can be targeted through immobilized metal affinity chromatography, or the presence of positively or negatively charged regions, which can be targeted by ion exchange resins. The resulting protocols enable the highly reproducible enrichment of low abundant proteins from serum, as demonstrated by the development and validation of a quantitative LC-MS method for sRAGE based on a strong cation exchange enrichment procedure. Our work furthermore emphasizes that protein concentrations must be seen in the context of the methodology that was used to measure them due to the complexity of the proteome and, as a consequence, the possibility that different methods may enrich a different subset of proteoforms. We showed further that ion exchange-based enrichment represents a relevant option for enriching other proteins of interest. However, for a rationally designed ion exchange-based enrichment procedure it is essential not to rely on the average, calculated isoelectric point of a protein but to study its charge distribution along the three-dimensional orientation of the molecule.
5.5.
SUPPORTING INFORMATION
The Tables S-2 
Figure S-2. Evaluation of the strength of the SCX loading and washing buffer (ammonium acetate, pH 10) based on LC-MS analyses of two unique sRAGE peptides (A) IGEPLVLK and (B) VLSPQGGGPWDSVAR
(N=2). The relative peak area, as presented on the y-axis, was calculated by dividing the peak area of the endogenous sRAGE signal by the peak area of the corresponding internal standard, which was added in an amount of 5 fmol per 50 µL serum. (NH 4 OH; pH appr. 11.5) or 0.1 M sodium hydroxide (NaOH) and samples were either dried directly or mixed with acetic acid (CH 3 COOH) or hydrochloric acid (HCl) to neutralize the pH prior to evaporating the samples to dryness. The relative peak area, as presented on the y-axis, was calculated by dividing the peak area of the endogenous sRAGE signal by the peak area of the corresponding internal standard, which was added in an amount of 5 fmol per 50 µL serum. a Protein isoelectric points were calculated for complete protein sequences using ExPASy's online ProtParam tool. b Protein concentrations were based on data from the Plasma Proteome Database, which was accessed in April 2018. In case more than one protein concentration was present in the database, available protein concentrations were averaged. In case entries consisted of a concentration range rather than a single concentration, the average of the presented range limits was calculated and this value was subsequently treated as a single concentration. c Peak areas presented in this table represent the peak areas as reported by the PEAKS software which were averaged for the six serum samples.
Figure S-3. Optimization of the SCX elution conditions based on LC-MS analyses of two unique sRAGE peptides (A) IGEPLVLK and (B) VLSPQGGGPWDSVAR (N=2). sRAGE was eluted with 1% ammonia
